Nymirum

Nymirum's mission is to unlock RNA capabilities with small molecules to accelerate innovation in medicine. Nymirum's DART platform allows you to quickly "decompose" and experimentally validate the dynamic structures of atomic resolution of target RNA, and then look at a large number of chemical compounds to identify other, more advanced, by structural optimization and design, compounds. Nymirum develops internal and external programs across several therapeutic areas and mechanisms of disease modification.

History

2021: Collaboration with Servier to find and develop RNA modulating drugs for the treatment of neurological diseases

The international independent pharmaceutical group Servier and Nymirum, a pioneer in the development of small molecules targeting RNA, have announced the launch of a joint research project aimed at finding and developing RNA-modulating drugs for the treatment of neurological diseases. This became known on July 14, 2021.

Under the collaboration agreement, Nymirum, through its proprietary patented DART platform (a target RNA platform with dynamically atomic resolution), will be responsible for developing small molecules that will form the basis of innovative drugs for neurodegenerative disease therapy. At the same time, Servier takes responsibility for conducting joint preclinical studies, and also receives the right to further develop candidate drugs and expand areas of cooperation. Nymirum will receive an advance payment for R&D as well as a financial reward if the joint project is successful.

We are pleased to combine the experience of Nymirum in the field of small molecules targeting target RNA with the expertise of Servier in the development of drugs for the treatment of diseases of the central nervous system. The ability to "lay out" and use the dynamic structure of RNA opens up opportunities for drug development in a variety of therapeutic areas, said Joshua Fairbank, chief executive officer and co-founder of Nymirum. - We hope for joint success in finding treatments for patients with severe neurological diseases.

"We are excited to work together with Nymirum on several projects aimed at creating new drugs to treat neurodegenerative diseases. To this end, we use DART, a platform for producing small molecules that target RNA. Compared to other DNA or RNA-based approaches, therapeutic solutions based on small molecules have a number of advantages and are very promising for further development in the field of treatment of patients suffering from diseases of the central nervous system, "said Ross Jeggo, head of neurological and immuno-inflammatory diseases at Servier.